These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
395 related articles for article (PubMed ID: 26386696)
1. BMI-related progression of atypical PKC-dependent aberrations in insulin signaling through IRS-1, Akt, FoxO1 and PGC-1α in livers of obese and type 2 diabetic humans. Sajan MP; Ivey RA; Farese RV Metabolism; 2015 Nov; 64(11):1454-65. PubMed ID: 26386696 [TBL] [Abstract][Full Text] [Related]
2. Coordinated regulation of hepatic FoxO1, PGC-1α and SREBP-1c facilitates insulin action and resistance. Sajan MP; Lee MC; Foufelle F; Sajan J; Cleland C; Farese RV Cell Signal; 2018 Mar; 43():62-70. PubMed ID: 29269047 [TBL] [Abstract][Full Text] [Related]
3. Hepatic insulin resistance in ob/ob mice involves increases in ceramide, aPKC activity, and selective impairment of Akt-dependent FoxO1 phosphorylation. Sajan MP; Ivey RA; Lee MC; Farese RV J Lipid Res; 2015 Jan; 56(1):70-80. PubMed ID: 25395359 [TBL] [Abstract][Full Text] [Related]
4. Akt-dependent phosphorylation of hepatic FoxO1 is compartmentalized on a WD40/ProF scaffold and is selectively inhibited by aPKC in early phases of diet-induced obesity. Sajan MP; Acevedo-Duncan ME; Standaert ML; Ivey RA; Lee M; Farese RV Diabetes; 2014 Aug; 63(8):2690-701. PubMed ID: 24705403 [TBL] [Abstract][Full Text] [Related]
5. Brain Insulin Signaling Is Increased in Insulin-Resistant States and Decreases in FOXOs and PGC-1α and Increases in Aβ1-40/42 and Phospho-Tau May Abet Alzheimer Development. Sajan M; Hansen B; Ivey R; Sajan J; Ari C; Song S; Braun U; Leitges M; Farese-Higgs M; Farese RV Diabetes; 2016 Jul; 65(7):1892-903. PubMed ID: 26895791 [TBL] [Abstract][Full Text] [Related]
6. Endurance exercise training increases APPL1 expression and improves insulin signaling in the hepatic tissue of diet-induced obese mice, independently of weight loss. Marinho R; Ropelle ER; Cintra DE; De Souza CT; Da Silva AS; Bertoli FC; Colantonio E; D'Almeida V; Pauli JR J Cell Physiol; 2012 Jul; 227(7):2917-26. PubMed ID: 21938726 [TBL] [Abstract][Full Text] [Related]
7. ALAS1 gene expression is down-regulated by Akt-mediated phosphorylation and nuclear exclusion of FOXO1 by vanadate in diabetic mice. Oliveri LM; Davio C; Batlle AM; Gerez EN Biochem J; 2012 Mar; 442(2):303-10. PubMed ID: 22070747 [TBL] [Abstract][Full Text] [Related]
8. Insulin signalling in hepatocytes of humans with type 2 diabetes: excessive production and activity of protein kinase C-ι (PKC-ι) and dependent processes and reversal by PKC-ι inhibitors. Sajan MP; Farese RV Diabetologia; 2012 May; 55(5):1446-57. PubMed ID: 22349071 [TBL] [Abstract][Full Text] [Related]
9. Correction of metabolic abnormalities in a rodent model of obesity, metabolic syndrome, and type 2 diabetes mellitus by inhibitors of hepatic protein kinase C-ι. Sajan MP; Nimal S; Mastorides S; Acevedo-Duncan M; Kahn CR; Fields AP; Braun U; Leitges M; Farese RV Metabolism; 2012 Apr; 61(4):459-69. PubMed ID: 22225955 [TBL] [Abstract][Full Text] [Related]
10. PGC-1alpha gene expression is down-regulated by Akt- mediated phosphorylation and nuclear exclusion of FoxO1 in insulin-stimulated skeletal muscle. Southgate RJ; Bruce CR; Carey AL; Steinberg GR; Walder K; Monks R; Watt MJ; Hawley JA; Birnbaum MJ; Febbraio MA FASEB J; 2005 Dec; 19(14):2072-4. PubMed ID: 16203862 [TBL] [Abstract][Full Text] [Related]
11. Increased insulin receptor substrate 2 expression is associated with steatohepatitis and altered lipid metabolism in obese subjects. Rametta R; Mozzi E; Dongiovanni P; Motta BM; Milano M; Roviaro G; Fargion S; Valenti L Int J Obes (Lond); 2013 Jul; 37(7):986-92. PubMed ID: 23147115 [TBL] [Abstract][Full Text] [Related]
12. Insulin-sensitive protein kinases (atypical protein kinase C and protein kinase B/Akt): actions and defects in obesity and type II diabetes. Farese RV; Sajan MP; Standaert ML Exp Biol Med (Maywood); 2005 Oct; 230(9):593-605. PubMed ID: 16179727 [TBL] [Abstract][Full Text] [Related]
13. PKCλ haploinsufficiency prevents diabetes by a mechanism involving alterations in hepatic enzymes. Sajan MP; Ivey RA; Lee M; Mastorides S; Jurczak MJ; Samuels VT; Shulman GI; Braun U; Leitges M; Farese RV Mol Endocrinol; 2014 Jul; 28(7):1097-107. PubMed ID: 24877563 [TBL] [Abstract][Full Text] [Related]
14. Metformin action in human hepatocytes: coactivation of atypical protein kinase C alters 5'-AMP-activated protein kinase effects on lipogenic and gluconeogenic enzyme expression. Sajan MP; Ivey RA; Farese RV Diabetologia; 2013 Nov; 56(11):2507-16. PubMed ID: 23933835 [TBL] [Abstract][Full Text] [Related]
15. Hepatic Activation of the FAM3C-HSF1-CaM Pathway Attenuates Hyperglycemia of Obese Diabetic Mice. Chen Z; Ding L; Yang W; Wang J; Chen L; Chang Y; Geng B; Cui Q; Guan Y; Yang J Diabetes; 2017 May; 66(5):1185-1197. PubMed ID: 28246289 [TBL] [Abstract][Full Text] [Related]
16. Combined thiazolidinedione-metformin treatment synergistically improves insulin signalling to insulin receptor substrate-1-dependent phosphatidylinositol 3-kinase, atypical protein kinase C and protein kinase B/Akt in human diabetic muscle. Temofonte N; Sajan MP; Nimal S; Pastoor T; Fumero C; Casaubon L; Powe JL; Standaert ML; Farese RV Diabetologia; 2009 Jan; 52(1):60-4. PubMed ID: 18972094 [TBL] [Abstract][Full Text] [Related]